Proliferative Activity in Libyan Breast Cancer with Comparison to European and Central African Patients

Table 2

Mean estimates (SD) of mitotic activity (SMI, MAI) in different  TNM stages and clinical stages of 130 Libyan female patients with breast cancer. The significance of correlation of stage features and proliferative features is shown as 𝑃  values evaluated with ANOVA and  𝑡-test.

Group	No. of patients	SMI (SD)	𝑃 value	MAI (SD)	𝑃 value
∗T Stage			0.03		0.06
T1	6	14.0 (11.3)		9.0 (9.2)
T2	45	28.5 (18.8)		26.6 (18.7)
T3	44	37.0 (25.4)		27.4 (19.2)
T4	35	33.5 (16.3)		31.0 (17.3)
∗∗N stage			0.007		0.02
N0	27	21.5 (13.0)		20.6 (19.7)
N1	69	34.2 (23.6)		28.6 (18.4)
N2	32	34.7 (16.7)		28.1 (16.1)
N3	2	60.1 (25.7)		57.5 (6.4)
∗∗∗M stage			0.06		0.1
M0	113	30.8 (20.0)		26.3 (18.4)
M1	16	41.3 (25.7)		33.9 (18.7)
Clinical stage			0.002		0.07
1	6	15.7 (9.3)		10.8 (8.1)
2	44	25.0 (14.5)		26.3 (20.8)
3	64	36.1 (22.2)		27.8 (16.7)
4	16	41.3 (21.0)		33.9 (18.7)

∗T stage: extent of the primary neoplasm; ∗∗N stage: lymph node status: extent of lymph node involvement; ∗∗∗M stage: distant metastasis, present/absent.